Navigation Links
Aesthera Announces Installation of 1000th Photopneumatic System in US
Date:6/4/2009

Over 1800 Systems Installed Worldwide in Under 4 years

PLEASANTON, Calif., June 4 /PRNewswire/ -- Aesthera today announced the installation of its 1000th Photopneumatic system in the United States. The installation of the 1000th system in the United States brings Aesthera's total installed base to approximately 1800 systems worldwide. The company has direct operations in the United States and Japan and a network of distributors in over 20 countries in Asia, Europe and the Middle East.

The 1000th Photopneumatic platform - the Isolaz Pro - was installed at the offices of Amy A. Vaughan, MD, of Amy A. Vaughan Dermatology, PLLC, a dermatologist in private practice in Barboursville, West Virginia. "Antibiotic resistance to acne is a growing concern for dermatologists and a rapidly growing number of physicians are moving away from using antibiotics as a primary weapon in the battle against acne. Even those physicians that do use antibiotics, often combine them with other treatment modalities that lessen drug resistance," says Dr. Vaughan. "Against this landscape, offering Isolaz treatments, especially to treat the more severe kinds of acne, was an obvious choice for our practice," she adds. Aesthera's Isolaz platform is the only FDA cleared device for the treatment of comedonal and pustular acne, in addition to a broad range of other indications, the company adds.

"The installation of our 1000th US system in less than 4 years post commercialization is a landmark achievement," says Alon Maor, Aesthera's President & CEO. During this period, the company commercialized its proprietary photopneumatic therapy, established the Isolaz as the premier treatment solution for acne and brought to market Profusion(TM) - a breakthrough skin therapy that combines Photopneumatic light treatments with the delivery of Aesthera's proprietary skincare to symbiotically enhance skin treatment outcomes for acne, body tightening, skin
'/>"/>

SOURCE Aesthera
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Aesthera Announces Breakthrough Innovations at 2009 American Academy of Dermatology (AAD) Meeting
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... network of signals active in almost all types of ... overdrive, and may help fuel a tumour,s uncontrolled growth, ... Cancer Research, London, identified a molecular trigger responsible for ... the cellular factory that makes the building blocks cancer ... the TOR signalling pathway, called SREBP, controls the flow ...
(Date:7/9/2014)... most common type of lung cancer, researchers have uncovered ... in forming tumors. The new knowledge may expand treatments ... changes already are available or are in clinical trials. ... from The Cancer Genome Atlas (TCGA), including researchers at ... Medical School and other institutions, studied tumors from 230 ...
(Date:7/9/2014)... New findings from Fox Chase Cancer Center paint a ... subset of breast cancers that have spread to the ... Tumors that grow into the skin, regardless of size ... classified as stage III and called "locally advanced" ... of cancer, often with poor survival. Locally advanced breast ...
(Date:7/9/2014)... used in policing injection drug users in Russia ... , A study, conducted by researchers from ... in collaboration with St. Petersburg Pavlov State University, ... on the health outcomes of a cohort of ... , Those who were arrested by police were ...
(Date:7/9/2014)... ITHACA, N.Y. Although feelings are personal and ... standard code that objectively represents emotions across different ... study by Cornell University neuroscientist Adam Anderson. , ... within the orbitofrontal cortex, an area of the ... neural code which captures an individual,s subjective feeling," ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Study cracks how the brain processes emotions 2
... ... ... Noni International (TNI) announced that Tahitian Noni® Bioactive Beverages™ contain iridoids —a bioactive ... for over 50 years and now 12 unique iridoids have been identified in the ...
... ... and after pictures and a directory for patients looking to find a plastic surgeon ... laser skin care. , ... (PRWEB) March 11, 2010 -- MyCosmeticProcedures.com is a new website focused ...
... , ... Technology Leadership with Largest Number of Highly Automated QT(sm) and QT Beat-to-Beat(sm) Studies ... Rochester, N.Y. (PRWEB) ... services and QT analysis, announced today that a top 10 pharmaceutical company has awarded ...
... LocalITCompanies.com ... be expanding nationwide. Local IT Companies connects businesses with up to three pre-screened IT service ... ... owners are entrenched in their own day to day business building operations and the thought ...
... Delphi ... Hospital in Hayward, California , ... Morrisville, NC (PRWEB) March 11, 2010 -- Delphi Healthcare Partners, Inc. ( ... provide a comprehensive OB/Gyn solution. With help from Delphi, St. Rose is in ...
... number of younger minority adults receiving medical care in settings ... the healthcare safety net). Poor, minority adults with moderate to ... to progress to kidney failure than non-Hispanic whites. These are ... Clinical Journal of the American Society of Nephrology (CJASN). ...
Cached Medicine News:Health News:12 Unique Iridoids Have Been Found in Noni Fruit 2Health News:New Website Connects Patients with Plastic Surgeons and Dermatologists 2Health News:New Website Connects Patients with Plastic Surgeons and Dermatologists 3Health News:New Website Connects Patients with Plastic Surgeons and Dermatologists 4Health News:Top 10 Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac 2Health News:LocalITCompanies.com now Helping Chicago, Dallas and Houston Businesses Find Pre-Screened IT Companies 2Health News:LocalITCompanies.com now Helping Chicago, Dallas and Houston Businesses Find Pre-Screened IT Companies 3Health News:Delphi Healthcare Partners Announces New Obstetrics/Gynecology Programs in Hayward, California 2Health News:Study: Kidney disease a big risk for younger, low-income minorities 2
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/14/2014)... Corporation (Nasdaq: LMNX ) today announced that it ... on Monday, February 3, 2014. A press release announcing the ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management ... and financial results for the fourth quarter and twelve months ...
(Date:1/14/2014)... , Jan. 14, 2014 Animal Emergency Critical Care, a ... Leesburg, Virginia is the first in ... chamber. Dr. Susan M. Barnes , Medical ... Barnes and husband, Dr. Cole Taylor , are avid scuba ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... Amarin Corporation plc (Nasdaq: AMRN ), a clinical-stage ... positive, statistically significant top-line results from its ANCHOR trial for ... met its primary and secondary efficacy endpoints for both the ... The purpose of the ANCHOR trial was to demonstrate that ...
... and SYDNEY, April 15, 2011 HeartWare International, ... a leading innovator of less invasive, miniaturized circulatory ... advanced heart failure, today announced the presentation of ... transplantation (BTT) study, ADVANCE, showing 180-day survival, using ...
Cached Medicine Technology:Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 2Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 3Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 4Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 5Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 6Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 7Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 8HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 2HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 3HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 4HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 5
Rosenbaum card fits in the pocket (3.5 by 6.5") and shows point, Jaeger and distance equivalents from 20/800 to 20/20. Uses numbers, directional Es and XO patterns. For use at 14" (35 mm). Includes f...
... contemporary reading card was designed by James ... of near point exercises including words, numbers ... 20/260, 20/200, 20/100, 20/65, 20/50, 20/40, 20/30, ... reading in English and metric, Jaeger, point ...
Standard reading test. "walked regularly..."...
Standard reading test. "Children should be..."...
Medicine Products: